M&As Most Active For Small China Biopharma Firms As Regulation Costs Bite
This article was originally published in PharmAsia News
Mergers & acquisitions among small- and medium-sized biopharma companies in China have witnessed strong momentum in the past year, with 31 completed since July 2012 and 61 in progress, according to a report.
You may also be interested in...
Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.